Development of cataract at · adults with centre‐involving diabetic macular oedema
It is very uncertain whether summary of findings: intravitreal bevacizumab plus intravitreal… changes development of cataract at compared with macular laser (very low certainty).
1 finding from 1 review
Raised Intraocular Pressure at · adults with centre‐involving diabetic macular oedema
It is very uncertain whether summary of findings: intravitreal bevacizumab plus intravitreal… changes raised Intraocular Pressure at compared with macular laser (very low certainty).
1 finding from 1 review
Systemic adverse events at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with centre‐involving diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Gain or loss of 10 or more letters visual acuity at 1 year · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in central macular thickness on OCT · adults with centre‐involving diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Significant intraocular inflammation at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of cataract at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Raised Intraocular Pressure at · adults with centre‐involving diabetic macular oedema
It is very uncertain whether summary of findings: intravitreal bevacizumab plus intravitreal… changes raised intraocular pressure at 1 year at compared with intravitreal steroid (very low certainty).
1 finding from 1 review
Systemic adverse events at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with centre‐involving diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Gain or loss of 10 or more letters visual acuity at 1 year · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD
1 finding from 1 review
Change in untransformed GA lesion size from baseline at 1 year (mm²) · adults with GA due to AMD
1 finding from 1 review
Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD
Summary of findings 1: Efficacy and safety of IVT lampalizumab… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham (low certainty).
1 finding from 1 review
Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD
Summary of findings 1: Efficacy and safety of IVT lampalizumab… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).
1 finding from 1 review
Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD
Summary of findings 1: Efficacy and safety of IVT lampalizumab… showed no clear difference in loss of ≥ 15 letters BCVA at 1 year compared with sham (moderate certainty).
1 finding from 1 review
Change in LLVA from baseline at 1 year (ETDRS letters) · adults with GA due to AMD
1 finding from 1 review